FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2920978728> ?p ?o ?g. }

• W2920978728 abstract "Abstract To summarize the therapeutic effects of PD-1/PD-L1 inhibitors on patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting, we attempted to identify potential molecular biomarkers or clinical factors that reflected the therapeutic effect. The medical records of patients with non-small cell lung cancer who were treated with PD-1/PD-L1 inhibitors were obtained from the outpatient department or inpatient department of Peking Union Medical College Hospital from August 1, 2015, to January 1, 2018. Our follow-up continued until May 1,2018. We chose overall survival (OS) as the primary observation endpoint and progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety as the secondary observation endpoints. Efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The Kaplan-Meier method was used to generate survival curves, and we compared the influence of different factors on PFS and OS by the log-rank test. The median follow-up time was 11 months. At the end of the follow-up, 24 patients (61.5%) were still undergoing immunotherapy, and 7 patients (17.9%) had died. Twenty-six cases (66.7%) employed PD-1/PD-L1 inhibitors as first-line treatment, and 7 cases (17.9%) employed PD-1/PD-L1 inhibitors as second-line treatment. Only 6 cases (15.4%) employed PD-1/PD-L1 inhibitors as third-line treatment. Therapeutic effect evaluation: Complete response (CR): 1 case (2.6%). Partial response (PR): 10 cases (25.6%). Stable disease (SD): 16 cases (41.0%). Progressive disease (PD): 12 cases (30.8%). The ORR was 28.2%, and DCR was 69.2%. The median PFS was 25.5 months (95% CI 6.8–44.1 months), which failed to reach the median OS. PD-1/PD-L1 inhibitor treatment is more effective for advanced non-small cell lung cancer patients in a real-world setting than in clinical trials; PD-1/PD-L1 inhibitor treatment is more effective for people who are over 70 than for people who are under 70. Additionally, patients who are over 75 years old have a higher response rate, suggesting that elderly patients may receive more benefits from immunotherapy; Patients who have an epidermal growth factor receptor (EGFR) mutation (+) may benefit from immunotherapy after treatment with a tyrosine kinase inhibitor (TKI). It is essential to identify these potential patients from the entire patient pool; PD-1 may have a certain curative effect on brain metastases from NSCLC. Local radiotherapy may help to improve PD-1 intracranial efficacy." @default.
• W2920978728 created "2019-03-22" @default.
• W2920978728 creator A5019634976 @default.
• W2920978728 creator A5056404061 @default.
• W2920978728 creator A5062081744 @default.
• W2920978728 creator A5066716873 @default.
• W2920978728 date "2019-03-12" @default.
• W2920978728 modified "2023-10-03" @default.
• W2920978728 title "Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors" @default.
• W2920978728 cites W1974820090 @default.
• W2920978728 cites W2011458181 @default.
• W2920978728 cites W2017736198 @default.
• W2920978728 cites W2019607817 @default.
• W2920978728 cites W2132870547 @default.
• W2920978728 cites W2170147411 @default.
• W2920978728 cites W2198093519 @default.
• W2920978728 cites W2293531514 @default.
• W2920978728 cites W2330914954 @default.
• W2920978728 cites W2466033276 @default.
• W2920978728 cites W2508060336 @default.
• W2920978728 cites W2559678440 @default.
• W2920978728 cites W2567564314 @default.
• W2920978728 cites W2760874344 @default.
• W2920978728 cites W2762777471 @default.
• W2920978728 cites W2767553670 @default.
• W2920978728 cites W2769455120 @default.
• W2920978728 cites W2777461561 @default.
• W2920978728 cites W2782157293 @default.
• W2920978728 cites W2890639244 @default.
• W2920978728 cites W2917911017 @default.
• W2920978728 doi "https://doi.org/10.1038/s41598-019-40748-7" @default.
• W2920978728 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6414649" @default.
• W2920978728 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30862891" @default.
• W2920978728 hasPublicationYear "2019" @default.
• W2920978728 type Work @default.
• W2920978728 sameAs 2920978728 @default.
• W2920978728 citedByCount "25" @default.
• W2920978728 countsByYear W29209787282019 @default.
• W2920978728 countsByYear W29209787282020 @default.
• W2920978728 countsByYear W29209787282021 @default.
• W2920978728 countsByYear W29209787282022 @default.
• W2920978728 countsByYear W29209787282023 @default.
• W2920978728 crossrefType "journal-article" @default.
• W2920978728 hasAuthorship W2920978728A5019634976 @default.
• W2920978728 hasAuthorship W2920978728A5056404061 @default.
• W2920978728 hasAuthorship W2920978728A5062081744 @default.
• W2920978728 hasAuthorship W2920978728A5066716873 @default.
• W2920978728 hasBestOaLocation W29209787281 @default.
• W2920978728 hasConcept C121608353 @default.
• W2920978728 hasConcept C126322002 @default.
• W2920978728 hasConcept C143998085 @default.
• W2920978728 hasConcept C203092338 @default.
• W2920978728 hasConcept C2776256026 @default.
• W2920978728 hasConcept C2777701055 @default.
• W2920978728 hasConcept C2778822529 @default.
• W2920978728 hasConcept C2779134260 @default.
• W2920978728 hasConcept C2779984678 @default.
• W2920978728 hasConcept C535046627 @default.
• W2920978728 hasConcept C71924100 @default.
• W2920978728 hasConceptScore W2920978728C121608353 @default.
• W2920978728 hasConceptScore W2920978728C126322002 @default.
• W2920978728 hasConceptScore W2920978728C143998085 @default.
• W2920978728 hasConceptScore W2920978728C203092338 @default.
• W2920978728 hasConceptScore W2920978728C2776256026 @default.
• W2920978728 hasConceptScore W2920978728C2777701055 @default.
• W2920978728 hasConceptScore W2920978728C2778822529 @default.
• W2920978728 hasConceptScore W2920978728C2779134260 @default.
• W2920978728 hasConceptScore W2920978728C2779984678 @default.
• W2920978728 hasConceptScore W2920978728C535046627 @default.
• W2920978728 hasConceptScore W2920978728C71924100 @default.
• W2920978728 hasIssue "1" @default.
• W2920978728 hasLocation W29209787281 @default.
• W2920978728 hasLocation W29209787282 @default.
• W2920978728 hasLocation W29209787283 @default.
• W2920978728 hasOpenAccess W2920978728 @default.
• W2920978728 hasPrimaryLocation W29209787281 @default.
• W2920978728 hasRelatedWork W1521559493 @default.
• W2920978728 hasRelatedWork W2035760218 @default.
• W2920978728 hasRelatedWork W2097545995 @default.
• W2920978728 hasRelatedWork W2114684119 @default.
• W2920978728 hasRelatedWork W2778655320 @default.
• W2920978728 hasRelatedWork W2889701300 @default.
• W2920978728 hasRelatedWork W2990680987 @default.
• W2920978728 hasRelatedWork W3009965978 @default.
• W2920978728 hasRelatedWork W3089163820 @default.
• W2920978728 hasRelatedWork W4303876191 @default.
• W2920978728 hasVolume "9" @default.
• W2920978728 isParatext "false" @default.
• W2920978728 isRetracted "false" @default.
• W2920978728 magId "2920978728" @default.
• W2920978728 workType "article" @default.